An international, multicenter, randomized, double-blind, 12-week controlled study of NGX-4010 [capsaicin] for treatment of painful HIV-associated neuropathy

Trial Profile

An international, multicenter, randomized, double-blind, 12-week controlled study of NGX-4010 [capsaicin] for treatment of painful HIV-associated neuropathy

Discontinued
Phase of Trial: Phase III

Latest Information Update: 04 Mar 2008

At a glance

  • Drugs Capsaicin (Primary)
  • Indications Neuropathic pain
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Mar 2008 Status changed from in progress to terminated (because of C107 findings demonstrating efficacy at doses of 90 and 30 min), according to ClinicalTrials.gov
    • 19 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top